Argus Research Adjusts CVS Health Price Target
Argus Research has revised its price target for CVS Health Corporation, lowering it from $114 to $105.
Stocks · News reference
CVS Health Executive Joins Atman Health Advisory Board
Dr. David Fairchild of CVS Health has been appointed to the Strategic Advisory Board of Atman Health to support the development of autonomous cardiovascular care.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
'State Democratic wins make Medicaid expansion a possibility for more than a million people' - STAT News
CVS Health Collaborates With Ronald McDonald House to Support Families
CVS Health continues its partnership with Ronald McDonald House Global, hosting Halloween-themed events and providing seasonal decor and care packages for families.
CVS Health Provides Strategic Update at 8th Annual Wolfe Research Healthcare Conference
CVS Health management discussed the company's planned separation into two independent businesses and provided updated expectations regarding separation-related dis-synergies.
CVS Pharmacy Announces Expanded Holiday Gift Assortment
CVS Pharmacy has introduced an expanded range of holiday gifts, including options for various budgets and celebrations.
CVS Health EVP and Group President Prem S. Shah Purchases $2 Million in Company Stock
Prem S. Shah, an Executive Vice President and Group President at CVS Health, acquired 23,855 shares of the company's common stock.